Molecular structure of Ritonavir, CAS Number: 155213-67-5
Ritonavir (CAS 155213-67-5)
See product citations (7)
Alternate Names:
Norvir, Norvir Softgel
Application:
Ritonavir is an inhibitor of HIV-1 protease
CAS Number:
155213-67-5
Purity:
≥98%
Molecular Weight:
720.94
Molecular Formula:
C37H48N6O5S2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Ritonavir is a compound that has been studied extensively in the context of its effects on various proteins, particularly enzymes involved in metabolic processes. In biochemical research, ritonavir is often used to investigate the mechanism of enzyme inhibition, with a focus on its interaction with and modulation of cytochrome P450 enzymes. This interaction is of interest due to the impact such compounds can have on the metabolism of other molecules. Additionally, ritonavir serves as a model compound in studies aiming to understand the kinetics and metabolic pathways of small molecules. In the field of biochemistry, ritonavir is also used to study protein binding and its effects on the activity and stability of proteins. Furthermore, its role in the modulation of signaling pathways is a subject of research, which contributes to the broader understanding of cellular response mechanisms.
Ritonavir (CAS 155213-67-5) References
- Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. | Saravolatz, LD., et al. 2023. Clin Infect Dis. 76: 165-171. PMID: 35245942
- Simultaneous green TLC determination of nirmatrelvir and ritonavir in the pharmaceutical dosage form and spiked human plasma. | Imam, MS., et al. 2023. Sci Rep. 13: 6165. PMID: 37061601
- The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data. | Petrakis, V., et al. 2023. Viruses. 15: PMID: 37112956
- Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19. | DeMarco, E., et al. 2023. SAGE Open Med Case Rep. 11: 2050313X231168304. PMID: 37113391
- Immediate COVID-19 treatment in CLL. | Niemann, CU. 2023. Blood. 141: 2167-2168. PMID: 37140952
- Adverse Events of SARS-CoV-2 Therapy: A Pharmacovigilance Study of the FAERS Database. | Pannu, V., et al. 2023. Ann Pharmacother. 10600280231169256. PMID: 37144730
- Tacrolimus toxicity due to enzyme inhibition from ritonavir. | Snee, I., et al. 2023. Am J Emerg Med. 69: 218.e5-218.e7. PMID: 37173153
- Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong. | Lui, DTW., et al. 2023. JAMA Netw Open. 6: e2314393. PMID: 37204790
- Physiologically-Based Pharmacokinetic Modeling of PAXLOVID™ with First-Order Absorption Kinetics. | Sagawa, K., et al. 2023. Pharm Res. 1-12. PMID: 37231296
- Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life. | Cegolon, L., et al. 2023. Pharmaceuticals (Basel). 16: PMID: 37242504
- Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19. | Lu, J., et al. 2023. Front Pharmacol. 14: 1161897. PMID: 37251313
- Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes. | Bajema, KL., et al. 2023. Ann Intern Med.. PMID: 37276589
- Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID-19. | Wu, JY., et al. 2023. J Med Virol. 95: e28866. PMID: 37314228
Inhibitor of:
20S Proteasome α3, AI747699, AKR7A5, Alphavirus, ASC2, ATP-binding cassette (ABC) transporter, AUH, Blood Group B antigen, BSEP, C20orf72, CapZ-β, CES7, CHCHD2, CMTM7, cornifelin, Coronavirus, CTRL, CYP26, CYP27A1, CYP2B13, CYP2B19, CYP2B23, CYP2B6, Cyp2c40, CYP2C8, CYP2D10, CYP2D11, CYP2D12, CYP2D22, CYP2D26, CYP2D34, CYP2D40, CYP2D9, CYP2S1, CYP2U1, CYP3A1, Cyp3a11, Cyp3a13, Cyp3a18, Cyp3a25, CYP3A4, CYP3A43, CYP3A5, CYP3A7-CYP3AP1, CYP4Z1, Cyp60, CYP8B1, cytochrome b5 type B, Dnajc22, Doc 4, Dokl, EG625716, Elmo3, ENGase, EXD, FDC-SP, GALK2, Glut14, HAGHL, Hep A, HIV gp24, HIV-1 p17, HIV-1 p55, HIV-1 Protease, HRASLS, IDI2, LOC729083, LPAAT-α, LSm10, Mast Cell Protease 1, MOXD1, mtTFA, NANP, OATP-B, OATP-H, OATP-I, Olfr250, Olfr509, OR1S2, OXNAD1, PIMT, PRX I, Rubella Virus gpE1, S3-12, SCCPDH, SLC25A29, SLMO2, SPBP, SR-2C, ST18, SUDD, Tom1L-1, tPA, TRIM5, UGT1A2, UGT1A5, UGT1A6A, UGT2A3, UNQ9438, V1RC19, and YadA.Activator of:
γ-GCSm, CYP2D12, CYP3A7, CYP3A7-CYP3AP1, CYPOR, GDF-15, HIV-1 Nef, HIV-2 gp36, LDH-AL6A, Oatp2, and Rubella Virus structural glycoprotein.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ritonavir, 10 mg | sc-208310 | 10 mg | $122.00 |